Coverage for prostate MRIs results in challenges for patients and referring physicians seeking to obtain ready access.
Private payers vary widely regarding provisions for prostate MRIs and are overly restrictive, according to a study published in the Journal of the American College of Radiology.
Researchers from the University of California in San Diego, UT Health San Antonio in Texas, and NYU Langone Health in New York city, investigated the national coverage landscape for prostate MRI services, assessing the presence of updated and accurate coverage requirements by private payers.
Using the database Policy Reporter, the researchers evaluated private payer coverage related to prostate MRI for 81 plans covering 149 million people in the United States. Both the indications and requirements for prostate MRI coverage were recorded in a variety of clinical scenarios, including initial diagnosis, staging, active surveillance, and suspected recurrence.
The results showed that overall, 11.1 percent of payers covered prostate MRI in biopsy-naïve patients with suspected prostate cancer; 88.9 percent required a prior negative biopsy. Nearly all payers also require either a rising prostate-specific antigen (PSA) or abnormal digital rectal examination (DRE). Rarely, a planned future MRI-targeted biopsy serves as a basis for MRI coverage.
Initial prostate cancer staging was covered by most payers, although typically with stringent indications, including PSA of 20 ng/mL or higher, Gleason score of seven or eight or higher, stage T3 or T4, or 20 percent or higher risk of nodal metastases. Only 10 payers discuss active surveillance, however eight required a repeat biopsy before MRI.
Coverage for detection of post-treatment recurrence often required a rising PSA or abnormal DRE, and occasionally only if a CT is first performed; only 10 of 81 payers address coverage after androgen deprivation treatment.
The researchers concluded that among private payers, prostate MRI coverage varied widely. The policies failed to recognize major clinical scenarios, were overly restrictive, and were often not reflective of current clinical practice, creating challenges for patients and referring physicians seeking to obtain ready access to prostate MRI services.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.